HIV Infections Clinical Trial
Official title:
Piloting At-birth Point of Care HIV Testing Strategies in Kenya
Innovative strategies to expedite HIV diagnosis among exposed infants, including at-birth testing and two portable point-of-care (POC) diagnostic systems, will be piloted using an implementation framework. The programmatic impact of these tools on early infant diagnosis (EID) will be measured in comparison with parallel standard of care (SOC) HIV DNA PCR testing initiated at 6 weeks of age.
Testing HIV-exposed infants by polymerase chain reaction (PCR) testing at 6 weeks is often
not early enough to mitigate the substantial mortality peak that occurs around 2-3 months of
age. Initial testing at birth would foster more rapid identification of infants with
intrauterine (IU) infection and speed up the initiation of antiretroviral therapy (ART) for
HIV-positive infants. Consequently, Kenya introduced new early infant diagnosis guidelines
recommending at-birth (0-2 weeks) virologic testing in addition to the SOC tests at 6 weeks
(6 - <24 weeks), 6 months and 12 months. POC testing performed in the clinic setting can
potentially further reduce the time to diagnosis. Investigators will pilot test the
implementation, performance, and cost-effectiveness of two POC test systems (Xpert HIV-1
Qual, Alere q HIV-1/2 Detect) in samples from neonates (at-birth test) and older infants
(6-week test) in four government hospitals in Kenya.
In the formative phase of the study, interviews will be conducted with parents, providers and
community members regarding benefits and concerns about the implementation of at-birth and
POC testing. Interviews with parents (pregnant women living with HIV and their partners if
available) will focus on the impact for the child and family. Interviews with providers who
would carry out POC testing at each site (maternity nurses, mentor mothers, hospital
laboratory staff) will highlight issues of training, logistics and implementation. Interviews
with community members (parents of HIV-exposed infants, community health workers, community
leaders) in surrounding communities will elicit attitudes and suggestions regarding the
potential for POC HIV testing in hard to access communities. Investigators will develop a
codebook with typical exemplars for each theme, calculating the frequency and distribution of
themes within the larger topic areas. The study team will rapidly review themes to inform the
POC pilot.
In the intervention phase the investigators will pilot at-birth and POC infant testing
strategies in four hospitals over a continuous 12-month enrollment period. Sites will be
randomized to pilot Xpert HIV-1 Qual (n=2) or Alere q HIV-1/2 Detect (n=2), both targeting
the at-birth and 6-week testing points. A second blood sample will be collected at each time
point to be tested by SOC laboratory-based HIV DNA PCR, which will correspond with the Kenya
government's 2016 guidelines that recommend adding an at-birth test to the EID schedule.
At-birth samples will ideally be collected within 24 hours of delivery and results
communicated to the mother with counseling prior to discharge from maternity. The expected
due dates of exposed infant will be tracked to encourage mothers who deliver outside the
hospital to return for infant testing within two weeks postnatal. Infants enrolled in this
pilot will be tracked until HIV results at birth and 6 weeks postnatal have been provided by
POC and standard PCR, or until ART is initiated for HIV-positive infants. Investigators will
assess user uptake, age at notification of HIV test results, age of ART initiation among HIV+
infants, POC machine performance, costs, and user experiences (providers will participate in
a monthly focus group to discuss challenges and solutions) to inform the feasibility and
optimal implementation of Kenya's 2016 at-birth test recommendation and of the mobile POC
test systems for the improvement of EID outcomes.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Recruiting |
NCT06033547 -
A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Two Different Formulations of Long-acting Cabotegravir in Healthy Adult Participants
|
Phase 1 | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT06072443 -
AURORA Study-A Transformative Approach to Support PrEP Medication Persistence
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 |